| 产品介绍 | | |
| Mouse anti Human BRCA1 antibody, clone MS110recognizes an epitope within the304 amino acid N-Terminal (NT) regionof human BRCA1, otherwise known as Breast cancer type 1 susceptibility protein, a tumor suppressor gene and major player in DNA damage repair, predominantly expressed in the nucleus during the S/G2 phase of the cell cycle.Deleterious BRCA1 mutations corralate with increased risk of cancers in both males and females including breast, pancreatic and prostate cancer, although in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations.BRCA1 is a key marker of triple-negative breast cancer/TNBC (ER-/PR-/HER2-), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and which lacks the benefit of specific therapy that targets the three major proteins ER/PR/HER2. Triple-negative tumors are predominantly basal-like, poorly differentiated and of higherhistological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women.Mouse anti human BRCA1 antibody, clone MS110 is suitable for use in both immunohistochemical and immunofluorescence staining of human breast and ovarian tissue, and clone MS110 is widely used and reported. |
| 产品详情 | | |
Target Species | Human |
| Product Form | Purified IgG - liquid |
| Preparation | Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant |
BufferSolution | TRIS-glycine buffered saline, NaCl |
Preservative Stabilisers | <0.1% Sodium Azide (NaN3) |
| Immunogen | Recombinant protein corresponding to the N-Terminal region of human BRCA1. |
| Approx. Protein Concentrations | IgG concentration 1.0 mg/ml |
| Fusion Partners | Spleen cells from immunized mice were fused with cells of the mouse NSI myeloma cell line. |
Regulatory | For research purposes only |
Guarantee | 12 monthsfrom date of despatch |
| 存储条件 | | |
| This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. |
| 应用 | | |
| Application Name | Verified | Min Dilution | Max Dilution |
| Flow Cytometry | √ | | Neat |
| Immunofluorescence | √ | | |
| Immunohistology - Frozen1 | √ | | |
| Immunohistology - Paraffin2 | √ | | |
| Immunoprecipitation | √ | | |
| Western Blotting | √ | | 1.0ug/ml |
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications fromthe originators. Please refer to references indicated for further information. For general protocol recommendations, please visit theantibody protocolspage.1This product requires antigen retrieval using heat treatment prior to staining of frozen sections. Sodium citrate buffer pH 6.0 is recommended for this purpose.SeeYoshikawa, K.et al.for details.2This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. Sodium citrate buffer pH 6.0 is recommended for this purpose.SeeYoshikawa, K.et al.for details.Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.- Histology Positive Control TissueBreast carcinoma
- Western BlottingMouse anti Human BRCA1 detects a band of approximately 220kDa in HeLa nuclear extract. A smaller band of 85kDa may also be seen, which may represent post-translational modification.
|
| 同型 |
| Description | Product Code | Applications | Pack Size |
| Mouse IgG1 Negative Control | MCA928 | Flow | 100 Tests |
| 相关产品 |
| Description | Product Code | Applications | Pack Size |
| Human Seroblock | BUF070A | Flow | 50 Tests |
| Human Seroblock | BUF070B | Flow | 200 Tests |
| 文献 |
| 1. Scully, R.et al.(1996) Location of BRCA1 in human breast and ovarian cancer cells.Science. 272 (5258): 123-6.2. Yoshikawa, K.et al.(1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.Clin Cancer Res. 5 (6): 1249-61.3. Scully, R.et al.(1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells.Cell. 88: 265-75.4. Chen, J. (2000) Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.Cancer Res. 60: 5037-9.5. Fraser, J.A.et al.(2003) A role for BRCA1 in sporadic breast cancer.Br J Cancer. 88: 1263-70.6. Kleiman, F.E.et al.(2005) BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.Genes Dev. 19: 1227-37.7. Pageau, G.J. and Lawrence, J.B. (2006) BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin.J Cell Biol. 175: 693-701. |
QQ:1749072012